Identification of tumour-related proteins as potential screening markers by proteome analysis—protein profiles of human saliva as a predictive and prognostic tool

EPMA Journal

Dietmar Thurnher¹  Elisabeth Drucker²  Kurt Krapfenbauer¹ 

[1] Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, A-1090 Vienna, Austria;Department of Molecular Biotechnology, University of Applied Science Vienna, Helmut-Qualtinger-Gasse 2, A-1090 Vienna, Austria

关键词: Patient self-management;    Disease monitoring;    Individual patient profiles;    Tailored therapy;    Targeted prevention;    Predictive medicine;    Saliva proteomics;    Oral squamous cell carcinoma;   

Others  :  1136529
DOI  :  10.1186/1878-5085-5-20

 received in 2014-10-30, accepted in 2014-11-11,  发布年份 2014

【 摘 要 】

The analysis of biomarkers in saliva as a clinical application offers an attractive, simple and rapid diagnostic tool for the short- and long-term monitoring of pathological disorders and drug therapy. The collection of saliva, either in the pure or in its fractionated form, is a relatively easy and non-invasive procedure that is not harmful to the patients and has no complications at all. However, the fluid collection must be clearly defined due to variations in saliva composition, flow rate and day-to-day variability. In order to minimise possible variations, saliva from five patients without squamous cell carcinoma (SCC) pathology and five with suspicion of oral squamous carcinoma (OSCC) were collected and matched at different days and analysed by two-dimensional polyacrylamide gel electrophoresis (2DE-PAGE). Approximately 800 spots were identified, corresponding to 151 different gene products. The list of identified proteins includes a large number of structural proteins like keratins, keratin subunits, enzymes and enzyme inhibitors, cytokines, immunoglobulins as well as amylase and other salivary specific glycoproteins. The majority of proteins that are localised in oral epithelia cells were found as unsolved debris in saliva. One of the identified proteins was significantly overexpressed in OSCC and was selected for further validation by Western blot analysis.

【 授权许可】

   
2014 Krapfenbauer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bray F, Sankila R, Ferlay J, Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002, 38(1):99-166.
• [2]Epstein JB, Zhang L, Rosin M: Advances in the diagnosis of oral premalignant and malignant. J Can Dent Assoc 2002, 68(10):617-621. Review
• [3]Mao L, Hong WK, Papadimitrakopoulou VA: Focus on head and neck cancer. Cancer Cell 2004, 5:311-316.
• [4]Ausweger C, Burgschwaiger E, Kugler A, Schmidbauer R, Steinek I, Todorov Y, Thurnher D, Krapfenbauer K: Economic concerns about global healthcare in lung, head and neck cancer: meeting the economic challenge of predictive, preventive and personalized medicine. EPMA J 2010, 1(4):627-631.
• [5]Koehn J, Krapfenbauer K, Huber S, Stein E, Sutter W, Watzinger F, Erovic BM, Thurnher D, Schindler T, Fountoulakis M, Turhani D: Potential involvement of MYC- and p53-related pathways in tumourigenesis in human oral squamous cell carcinoma revealed by proteomic analysis. J Proteome Res 2008, 7(9):3818-3829.
• [6]Zielinski V, Brunner M, Heiduschka G, Schneider S, Seemann R, Erovic B, Thurnher D: ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study. BMC Cancer 2012, 27:12-76.
• [7]Nagler RM, Barak M, Ben-Aryeh H, Peled M, Filatov M, Laufer D: Early diagnostic and treatment monitoring role of Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 1999, 35:1018-1025.
• [8]Bhatavdekar JM, Patel DD, Vora HH, Balar DB: Circulating markers and growth factors as prognosticators in men with advanced tongue cancer. Tumour Biol 1993, 14:55-58.
• [9]Bhatavdekar JM, Patel DD, Vora HH, Balar DB: Circulating prolactin and TPS in monitoring the clinical course of male patients with metastatic tongue cancer: a preliminary study. Anticancer Res 1993, 13:237-240.
• [10]Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ: A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol 1998, 23:82-86.
• [11]Hellner D, Klapdor R, Gundlach KH, Schmelze R: Results with the use of the SCC antigen in squamous cell carcinomas of the oral cavity. Dtsch Z Mund Kiefer Gesichtschir 1989, 13:291295.
• [12]Zoller J, Fiehn W, Mende U, Hotz G: The diagnostic value of the tumour markers CEA, “Ca 19–9”, “Ca 125”, “Ca15–3”, and “SCC” for the detection of recurrent tumours in patients with tumours of the head and neck. Dtsch Z Mund Kiefer Gesichtschir 1990, 14:254-259.
• [13]Zoller J: The value of “tumour markers” in the therapy and aftercare of carcinoma of the oral mucosa. Dtsch Zahn Mund Kieferheilkd Zentralbl 1992, 80:351-357.
• [14]Kuo WR, Lee KW, Ho KY, Tsai SM, Chiang FY, Juan KH: Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumour markers in squamous cell carcinoma of the head and neck. Kaohsiung J Med Sci 1999, 15:152-158.
• [15]Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N: Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. J Craniomaxillofac Surg 1998, 26:2438-2445.
• [16]Hoffmann J, Munz A, Krimmel M, Alfter G: Intraoperative and postoperative kinetics of serum tumour markers in patients with oral carcinoma. J Oral Maxillofac Surg 1998, 56:1390-1393.
• [17]Kurokawa H, Tsuru S, Okada M, Nakamura T, Kajiyama M: Evaluation of tumour markers in patients with squamous cell carcinoma in the oral cavity. Int J Oral Maxillofac Surg 1993, 22:35-38.
• [18]Kurokawa H, Yamashita Y, Tokudome S, Kajiyama M: Combination assay for tumour markers in oral squamous cell carcinoma. J Oral Maxillofac Surg 1997, 55:964-966.
• [19]Ziober AF, Patel KR, Alawi F, Gimotty P, Weber RS, Feldman MM, Chalian AA, Weinstein GS, Hunt J, Ziober BL: Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin Cancer Res 2006, 12(20 Pt 1):5960-5971.
• [20]Hunt LP: Reviewing the reviews: some thoughts from the JLO statistical advisor. J Laryngol Otol 2006, 120(2):85-86.
• [21]Molloy MP, Brzezinski EE, Hang J, McDowell MT, VanBogelen RA: Overcoming technical variation and biological variation in quantitative proteomics. Proteomics 2003, 3(10):1912-1919.
• [22]Karp NA, Spencer M, Lindsay H, O’Dell K, Lilley KS: Impact of replicate types on proteomic expression analysis. J Proteome Res 2005, 4(5):1867-1871.
• [23]Li Y, Zhou X, St. John MAR, Wong DT: RNA profiling of cell-free saliva using microarray technology. J Dent Res 2004, 83:199-203.
• [24]Sidransky D: Emerging molecular markers of cancer. Nat Rev Cancer 2002, 2:210-219.
• [25]Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49-53.
• [26]Liu T, Wahlberg S, Burek E, Lindblom P, Rubio C, Lindblom A: Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer. Genes Chromosomes Cancer 2000, 27:17-25.
• [27]Groden J, Thliveris A, Samowitz W: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66:589-600.
• [28]Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 1997, 278:1054-1059.
• [29]Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18:65-73.
• [30]Rieger-Christ KM, Mourtzinos A, Lee PJ: Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumour detection. Cancer 2003, 98:737-744.
• [31]Wong LJ, Lueth M, Li XN, Lau CC, Vogel H: Detection of mitochondrial DNA mutations in the tumour and cerebrospinal fluid of medulloblastoma patients. Cancer Res 2003, 63:3866-3871.
• [32]Kopreski MS, Benko FA, Gocke CD: Circulating RNA as a tumour marker: detection of 5 T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci 2001, 945:172-178.
• [33]Bunn PJ Jr: Early detection of lung cancer using serum RNA or DNA markers: ready for “prime time” or for validation? J Clin Oncol 2003, 21:3891-3893.
• [34]Lawrence HP: Salivary markers of systemic disease: non-invasive diagnosis of disease and monitoring of general health. J Can Dent Assoc 2002, 68:170-174.
• [35]El-Naggar AK, Mao L, Staerkel G: Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn 2001, 3:164-170.
• [36]Liao PH, Chang YC, Huang MF, Tai KW, Chou MY: Mutation of p53 gene codon 63 in saliva as a molecular marker for oral squamous cell carcinomas. Oral Oncol 2000, 36:272-276.
• [37]Patel V, Leethanakul C, Gutkind JS: New approaches to the understanding of the molecular basis of oral cancer. Crit Rev Oral Biol Med 2001, 12(1):55-63. Review
• [38]Herrmann PC, Liotta LA, Petricoin EF: Cancer proteomics: the state of the art. Dis Markers 2001, 17(2):49-57. Review
• [39]He Q, Chen J, Kung HF, Yuen A, Chiu JF: Identification of tumour-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004, 4:271-278.
• [40]Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, Reed SG: Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000, 110:374-381.
• [41]Klijanienko J, el-Naggar A, De Braud F, Micheau C, Janot F, Luboinski B, Gentile A, Russo A, Cvitkovic E: Keratins 6, 13 and 19. Differential expression in squamous cell carcinoma of the head and neck. Anal Quant Cytol Histol 1993, 15(5):335-340.
• [42]Giannini F, Maestro R, Vukosavljevic T, Pomponi F, Boiocchi M: All-trans, 13-cis and 9-cis retinoic acids induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Int J of Canc 1997, 70:194-200.
• [43]Croxtall JD, Gilroy DW, Solito E, Choudhury Q, Ward BJ, Buckingham JC, Flower RJ: Attenuation of glucocorticoid functions in an Anx-A1−/− cell line. Biochem J 2003, 371(Pt 3):927-935.
• [44]Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235.
• [45]Chen J, He QY, Yuen AP, Chiu JF: Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumourigenesis. Proteomics 2004, 4:2465-2475.
• [46]Pena-Alonso E, Rodrigo JP, Parra IC, Pedrero JM, Meana MV, Nieto CS, Fresno MF, Morgan RO, Fernandez MP: Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett 2008, 263(1):89-98.
• [47]Bouden GT, Krieg P: Differential gene expression during multistage carcinogenesis. Environ Health Perspect 1991, 93:51-56.
• [48]Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin EF: Loss of annexin 1 correlates with early onset of tumourigenesis in esophageal and prostate carcinoma. Cancer Res 2000, 60:6293-6297.
• [49]Tada H, Hatoko M, Tanaka A, Kuwahara M, Muramatsu T: Expression of desmoglein I and plakoglobin in skin carcinomas. J Cutan Pathol 2000, 27:24-29.
• [50]Golubnitschaja O, Costigliola V, EPMA: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J 2012, 3(1):14. BioMed Central Full Text
• [51]Golubnitschaja O, Kinkorova J, Costigliola V: Predictive, Preventive and Personalised Medicine as the hardcore of “Horizon 2020”: EPMA position paper. EPMA J 2014, 5(1):6. BioMed Central Full Text